SITC - November 2020

SITC - November 2020

  • Society for Immunotherapy of Cancer (SITC) is one of the key conferences dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy
  • SITC 2020 highlighted the major advancements in cancer research. Among the cancer immunotherapies, anti-PD1/L1 has been the key MOA of interest
  • Here in this digest, we provide a quantitative view of the on-going trials with anti-PD1/L1 therapies and  combinations

Home